A5031483568- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Social Media in Health Education
- Bladder and Urothelial Cancer Treatments
- Urologic and reproductive health conditions
- Health Literacy and Information Accessibility
- Global Cancer Incidence and Screening
- Patient-Provider Communication in Healthcare
- Colorectal Cancer Screening and Detection
- Genital Health and Disease
- Statistical Methods in Clinical Trials
- Health Systems, Economic Evaluations, Quality of Life
- Urological Disorders and Treatments
- COVID-19 and healthcare impacts
- BRCA gene mutations in cancer
- Urinary Bladder and Prostate Research
- Misinformation and Its Impacts
- Ethics in Clinical Research
- Sexual function and dysfunction studies
- Cancer, Lipids, and Metabolism
- Molecular Biology Techniques and Applications
- Urinary Tract Infections Management
- Cancer survivorship and care
- Renal cell carcinoma treatment
- Economic and Financial Impacts of Cancer
NYU Langone Health
2015-2025
Veterans Health Administration
2016-2025
New York University
2016-2025
VA NY Harbor Healthcare System
2013-2023
National Hospital
2022
Johns Hopkins University
2007-2022
NYU Langone’s Laura and Isaac Perlmutter Cancer Center
2016-2022
GTx (United States)
2018-2022
Population Council
2019-2021
Manhattan Psychiatric Center
2016-2021
More than 1 million prostate biopsies are performed annually among Medicare beneficiaries. We determined the risk of serious complications requiring hospitalization. hypothesized that with emerging multidrug resistant organisms there may be an increasing infectious complications.In a 5% random sample participants in SEER (Surveillance, Epidemiology and End Results) regions from 1991 to 2007 we compared 30-day hospitalization rates ICD-9 primary diagnosis codes for admissions between 17,472...
Prostate specific antigen and free prostate have limited specificity to detect clinically significant, curable cancer, leading unnecessary biopsy, detection treatment of some indolent tumors. Specificity significant cancer may be improved by [-2]pro-prostate antigen. We evaluated antigen, using the formula, ([-2]pro-prostate antigen/free × antigen(1/2)) enhance overall high grade cancer.
To assess the predictive ability of prostate-specific antigen (PSA) velocity (PSAV) and doubling time (PSADT) for biopsy progression adverse pathology at prostatectomy among men with low-risk prostate cancer enrolled on an active-surveillance program.We evaluated 290 who met criteria active surveillance (ie, PSA density < 0.15 ng/mL/cm(3) Gleason score or = 6 no pattern > 4, involving 2 cores cancer, 50% involvement any core by cancer) two more serial measurements after diagnosis from 1994...
The Prostate Health Index (phi) is a new test combining total, free and [-2]proPSA into single score. It was recently approved by the FDA now commercially available in U.S., Europe Australia. We investigate whether phi improves specificity for detecting clinically significant prostate cancer can help reduce over diagnosis.From multicenter prospective trial we identified 658 men age 50 years or older with specific antigen 4 to 10 ng/ml normal digital rectal examination who underwent biopsy....
Germline testing (GT) is a central feature of prostate cancer (PCA) treatment, management, and hereditary assessment. Critical needs include optimized multigene strategies that incorporate evolving genetic data, consistency in GT indications alternate evaluation models address the rising demand for services. A multidisciplinary consensus conference included experts, stakeholders, national organization leaders was convened response to current practice challenges develop implementation...
Purpose It is clinically challenging to integrate genomic-classifier results that report a numeric risk of recurrence into treatment recommendations for localized prostate cancer, which are founded in the framework groups. We aimed develop novel clinical-genomic grouping system can readily be incorporated guidelines cancer. Materials and Methods Two multicenter cohorts (n = 991) were used training validation groups, two additional 5,937) reclassification analyses. Competing risks analysis...
Importance Consumers are increasingly using artificial intelligence (AI) chatbots as a source of information. However, the quality cancer information generated by these has not yet been evaluated validated instruments. Objective To characterize and presence misinformation about skin, lung, breast, colorectal, prostate cancers 4 AI chatbots. Design, Setting, Participants This cross-sectional study assessed chatbots’ text responses to 5 most commonly searched queries related common Search data...
The Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) recommendations standardise the reporting prostate magnetic resonance imaging (MRI) patients on active surveillance (AS) for cancer. An international consensus group recently updated these and identified areas uncertainty.
Innovations have improved outcomes in advanced prostate cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that greatly impact daily practice. The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) surveyed experts key questions clinical management order supplement evidence-based guidelines. Here present voting results for from APCCC 2024.